(NASDAQ: JAZZ) Jazz Pharmaceuticals's forecast annual revenue growth rate of 5.17% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.17%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.45%.
Jazz Pharmaceuticals's revenue in 2026 is $4,601,233,000.On average, 23 Wall Street analysts forecast JAZZ's revenue for 2026 to be $299,191,285,393, with the lowest JAZZ revenue forecast at $280,041,485,178, and the highest JAZZ revenue forecast at $317,432,281,530. On average, 23 Wall Street analysts forecast JAZZ's revenue for 2027 to be $320,093,779,187, with the lowest JAZZ revenue forecast at $287,571,576,110, and the highest JAZZ revenue forecast at $342,554,222,829.
In 2028, JAZZ is forecast to generate $348,850,936,798 in revenue, with the lowest revenue forecast at $296,529,787,736 and the highest revenue forecast at $413,765,513,798.